A key activity of SPEAC (Safety Platform for Emergency vACcines) has been to establish lists of adverse events of special interest (AESI) that have potential to occur during CEPI funded clinical trials. The initial landscape analysis for Rift Valley Fever AESI was completed in March 2020 and was based on a non-systematic literature review of key articles. RVF clinical trials are due to commence within the year in East African sites and thus an update to the RVF AESI list is a high priority for CEPI. The primary objective was to conduct a scoping review of literature published after the previous landscape analysis in order to determine whether or not any new AESI should be added to the previous AESI list for novel Rift Valley Fever vaccines. No new AESI were identified as a result of this updated landscape analysis for Rift Valley Fever as a disease, however several new AESI are associated with vaccine platforms. An updated version of the AESI list is included in the document. This includes additional platform-specific AESI, based on experience with COVID-19 vaccines. It also provides an update as to which AESI have published case definitions and companion guides.

The SPEAC Project is funded in whole by CEPI.